Austar Lifesciences Ltd. (HK:6118) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Austar Lifesciences Limited has released its interim financial results for the first half of 2024, showcasing a return to profitability with a profit before income tax of RMB 9,186,000, compared to a loss in the same period in 2023. The company reported a gross profit of RMB 145,417,000 and a modest increase in gross profit margin to 20.75%, despite a decrease in revenue from the previous year. The results indicate a positive shift in the company’s financial performance, with basic and diluted earnings per share both at RMB 0.01.
For further insights into HK:6118 stock, check out TipRanks’ Stock Analysis page.